Previous 10 | Next 10 |
Rezolute (NASDAQ:RZLT): Q1 GAAP EPS of -$0.92 misses by $0.02. Cash and cash equivalents totaled $37.3M Press Release For further details see: Rezolute EPS misses by $0.02
REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the first quarter...
Rezolute (NASDAQ: RZLT) , a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, has announced the pricing of an underwritten public offering. The offering consists of 6,030,847 shares of its common st...
Gainers: Jasper (NASDAQ:JSPR) +127%. Waitr Holdings (NASDAQ:WTRH) +55%. Clarus Therapeutics Holdings (NASDAQ:CRXT) +46%. Sono-Tek (NASDAQ:SOTK) +26%. Paltalk (NASDAQ:PALT) +21%. Statera Biopharma (NASDAQ:STAB) +20%. SMART Global Holdings (NASDAQ:SGH) +15%. NeuroBo Pharmaceuticals (NASDAQ:NRBO...
Gainers: Jasper Therapeutics JSPR +114%, Clarus Therapeutics (NASDAQ:CRXT) +45%, Alimera Sciences ALIM +19%, Revance Therapeutics RVNC +13%, Recursion Pharmaceuticals (NASDAQ:RXRX) +12%. Losers: NeuroOne Medical Technologies NMTC -25%, Ne...
REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, t...
REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, t...
Continuous glucose monitoring reveals undertreated hypoglycemia in patients with congenital hyperinsulinism RZ358, a monoclonal antibody in Phase 2b development, has normalized blood glucose levels in prior studies REDWOOD CITY, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- ...
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the fourth quart...
Tracking to Announce Top line data in Q1 2022 REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalan...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that the underwr...
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of i...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...